Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance

por Jotte, Robert M, Spigel, David R
Publicado 2015

Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)

por ZINNER, RALPH, GRUL, CARLA VISSEREN, SPIGEL, DAVID R., OBASAJU, COLEMAN
Publicado 2015

 A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

por Johnson, Melissa L, Patel, Manish R, Aljumaily, Raid, Jones, Suzanne F, Burris, III, Howard A, Spigel, David R
Publicado 2023

A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors

por Falchook, Gerald S, Sachdev, Jasgit, Imedio, Esteban Rodrigo, Kumar, Sanjeev, Mugundu, Ganesh M, Jenkins, Suzanne, Chmielecki, Juliann, Jones, Suzanne, Spigel, David R, Johnson, Melissa
Publicado 2023

Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohor...

por Burris, Howard A, Bakewell, Suzanne, Bendell, Johanna C, Infante, Jeffrey, Jones, Suzanne F, Spigel, David R, Weiss, Glen J, Ramanathan, Ramesh K, Ogden, Angela, Von Hoff, Daniel
Publicado 2017

Discordance in Tumor Mutation Burden from Blood and Tissue Affects Association with Response to Immune Checkpoint Inhibition in Real-World Settings

por Sturgill, Emma G, Misch, Amanda, Jones, Carissa C, Luckett, Daniel, Fu, Xiaotong, Schlauch, Dan, Jones, Suzanne F, Burris, Howard A, Spigel, David R, McKenzie, Andrew J
Publicado 2022

nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2

por Gajra, Ajeet, Karim, Nagla Abdel, Mulford, Deborah A., Villaruz, Liza Cosca, Matrana, Marc Ryan, Ali, Haythem Y., Santos, Edgardo S., Berry, Tymara, Ong, Teng Jin, Sanford, Alexandra, Amiri, Katayoun, Spigel, David R.
Publicado 2018

JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer

por Ramalingam, Suresh S., Thara, Eddie, Awad, Mark M., Dowlati, Afshin, Haque, Basir, Stinchcombe, Thomas E., Dy, Grace K., Spigel, David R., Lu, Sharon, Iyer Singh, Nithya, Tang, Yongqiang, Teslenko, Iryna, Iannotti, Nicholas
Publicado 2021

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First‐Line Nonsquamous Non‐Small Cell Lung Cancer...

por von Pawel, Joachim, Spigel, David R., Ervin, Thomas, Losonczy, György, Barlesi, Fabrice, Juhász, Erzsébet, Anderson, Maria, McCall, Bruce, Wakshull, Eric, Hegde, Priti, Ye, Weilan, Chen, Daniel, Chang, Ilsung, Rhee, Ina, Reck, Martin
Publicado 2018

Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study

por Friedman, Claire F., Hainsworth, John D., Kurzrock, Razelle, Spigel, David R., Burris, Howard A., Sweeney, Christopher J., Meric-Bernstam, Funda, Wang, Yong, Levy, Jonathan, Grindheim, Jessica, Shames, David S., Schulze, Katja, Patel, Arisha, Swanton, Charles
Publicado 2022

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, p...

por George, Daniel J, Spigel, David R, Gordan, Lucio N, Kochuparambil, Samith T, Molina, Ana M, Yorio, Jeff, Rezazadeh Kalebasty, Arash, McKean, Heidi, Tchekmedyian, Nishan, Tykodi, Scott S, Zhang, Joshua, Askelson, Margarita, Johansen, Jennifer L, Hutson, Thomas E
Publicado 2022

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032

por Ready, Neal, Farago, Anna F., de Braud, Filippo, Atmaca, Akin, Hellmann, Matthew D., Schneider, Jeffrey G., Spigel, David R., Moreno, Victor, Chau, Ian, Hann, Christine L., Eder, Joseph Paul, Steele, Nicola L., Pieters, Anne, Fairchild, Justin, Antonia, Scott J.
Publicado 2018

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy

por Thomas, Michael, Spigel, David R, Jotte, Robert M, McCleod, Michael, Socinski, Mark A, Page, Ray D, Gressot, Laurent, Knoble, Jeanna, Juan, Oscar, Morgensztern, Daniel, Isla, Dolores, Kim, Edward S, West, Howard, Ko, Amy, Ong, Teng Jin, Trunova, Nataliya, Gridelli, Cesare
Publicado 2017

Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell...

por Salgia, Ravi, Weaver, R. Waide, McCleod, Michael, Stille, John R., Yan, S. Betty, Roberson, Stephanie, Polzer, John, Flynt, Amy, Raddad, Eyas, Peek, Victoria L., Wijayawardana, Sameera R., Um, Suzane L., Gross, Steve, Connelly, Mark C., Morano, Carrie, Repollet, Madeline, Sanders, Renouard, Baeten, Kurt, D’Haese, David, Spigel, David R.
Publicado 2017

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC

por Gray, Jhanelle E., Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Hui, Rina, Kurata, Takayasu, Chiappori, Alberto, Lee, Ki Hyeong, Cho, Byoung Chul, Planchard, David, Paz-Ares, Luis, Faivre-Finn, Corinne, Vansteenkiste, Johan F., Spigel, David R., Wadsworth, Catherine, Taboada, Maria, Dennis, Phillip A., Özgüroğlu, Mustafa, Antonia, Scott J.
Publicado 2019

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)

por Hodi, F. Stephen, Chapman, Paul B., Sznol, Mario, Lao, Christopher D., Gonzalez, Rene, Smylie, Michael, Daniels, Gregory A., Thompson, John A., Kudchadkar, Ragini, Sharfman, William, Atkins, Michael, Spigel, David R., Pavlick, Anna, Monzon, Jose, Kim, Kevin B., Ernst, Scott, Khushalani, Nikhil I., van Dijck, Wim, Lobo, Maurice, Hogg, David
Publicado 2020

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed...

por Zinner, Ralph G., Obasaju, Coleman K., Spigel, David R., Weaver, Robert W., Beck, J. Thaddeus, Waterhouse, David M., Modiano, Manuel R., Hrinczenko, Borys, Nikolinakos, Petros G., Liu, Jingyi, Koustenis, Andrew G., Winfree, Katherine B., Melemed, Symantha A., Guba, Susan C., Ortuzar, Waldo I., Desaiah, Durisala, Treat, Joseph A., Govindan, Ramaswamy, Ross, Helen J.
Publicado 2015

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

por Waterhouse, David M., Garon, Edward B., Chandler, Jason, McCleod, Michael, Hussein, Maen, Jotte, Robert, Horn, Leora, Daniel, Davey B., Keogh, George, Creelan, Ben, Einhorn, Lawrence H., Baker, Justin, Kasbari, Samer, Nikolinakos, Petros, Babu, Sunil, Couture, Felix, Leighl, Natasha B., Reynolds, Craig, Blumenschein, George, Gunuganti, Vijay, Li, Ang, Aanur, Nivedita, Spigel, David R.
Publicado 2020

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

por Topalian, Suzanne L., Hodi, F. Stephen, Brahmer, Julie R., Gettinger, Scott N., Smith, David C., McDermott, David F., Powderly, John D., Sosman, Jeffrey A., Atkins, Michael B., Leming, Philip D., Spigel, David R., Antonia, Scott J., Drilon, Alexander, Wolchok, Jedd D., Carvajal, Richard D., McHenry, M. Brent, Hosein, Fareeda, Harbison, Christopher T., Grosso, Joseph F., Sznol, Mario
Publicado 2019

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results

por Yap, Timothy A., Fontana, Elisa, Lee, Elizabeth K., Spigel, David R., Højgaard, Martin, Lheureux, Stephanie, Mettu, Niharika B., Carneiro, Benedito A., Carter, Louise, Plummer, Ruth, Cote, Gregory M., Meric-Bernstam, Funda, O’Connell, Joseph, Schonhoft, Joseph D., Wainszelbaum, Marisa, Fretland, Adrian J., Manley, Peter, Xu, Yi, Ulanet, Danielle, Rimkunas, Victoria, Zinda, Mike, Koehler, Maria, Silverman, Ian M., Reis-Filho, Jorge S., Rosen, Ezra
Publicado 2023